Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
Holding NMRA?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.44Last Year’s EPS
-0.71Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 07, 2024
|% Change Since: -84.09%
|Next Earnings Date:Nov 01, 2023
Earnings Call Sentiment|Positive
The earnings call highlighted Neumora's robust clinical pipeline and financial position, with promising developments in their lead program, Navacaprant. However, increased operating expenses and the inherent challenges in CNS drug development were noted.Company Guidance
During Neumora Therapeutics' Q3 2024 earnings call, the company provided guidance on its robust portfolio and upcoming milestones. The discussion highlighted the advancement of Navacaprant, a novel kappa opioid receptor antagonist, with three Phase III studies—KOASTAL-1, KOASTAL-2, and KOASTAL-3—aimed at treating Major Depressive Disorder (MDD), targeting a total enrollment of approximately 332 patients each. The company anticipates top-line data from KOASTAL-1 by the end of 2024, with KOASTAL-2 and KOASTAL-3 results expected in the first half of 2025. Financially, Neumora reported operating expenses of $76.6 million for Q3 2024, up from $56.9 million in 2023, and ended the quarter with $341.3 million in cash, expected to fund operations into mid-2026. The call also outlined the company's strategy to leverage its cash position to support five upcoming clinical catalysts over the next 18 months, including Navacaprant studies in both MDD and bipolar depression, and NMRA-511 in Alzheimer's disease agitation.Strong Financial Position
Neumora ended Q3 2024 with $341.3 million in cash, cash equivalents, and marketable securities, expected to support operations into mid-2026.
Robust Clinical Pipeline
Neumora has developed a portfolio of 7 clinical and preclinical programs targeting novel mechanisms of action, including Navacaprant for Major Depressive Disorder and NMRA-511 for Alzheimer's disease agitation.
Navacaprant Phase III Trials
Three Phase III trials (KOASTAL-1, KOASTAL-2, KOASTAL-3) for Navacaprant in Major Depressive Disorder are ongoing, with results from KOASTAL-1 expected by the end of the year.
Positive Phase II Results for Navacaprant
Navacaprant showed efficacy in treating depressive symptoms, including anhedonia, with a favorable safety profile in Phase II.
Advancements in Alzheimer's and Bipolar Disorder Studies
A Phase Ib study of NMRA-511 in Alzheimer's disease agitation is ongoing, with results expected in 2025. A Phase II study for Navacaprant in bipolar disorder is also advancing.
---
NMRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NMRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $13.64 | $11.31 | -17.08% |
| Aug 06, 2024 | $11.96 | $11.99 | +0.25% |
| May 07, 2024 | $9.35 | $9.81 | +4.92% |
| Mar 07, 2024 | $18.40 | $19.00 | +3.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neumora Therapeutics, Inc. (NMRA) report earnings?
Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Neumora Therapeutics, Inc. (NMRA) earnings time?
Neumora Therapeutics, Inc. (NMRA) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMRA EPS forecast?
NMRA EPS forecast for the fiscal quarter 2024 (Q4) is -0.44.
---